Bayoclin SRL
Bayoclin reported total assets of 269,763 € at the end of the 2025 financial year (annual accounts filed with the NBB on 27 Apr 2026).
The score of Bayoclin shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity +61 % Total assets +37 %
Accounts of the company itself (not consolidated).
The full file covers 4 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Bayoclin's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 27 Apr 2026
- Year ended 31 Dec 2024filed on 12 Jun 2025
- Year ended 31 Dec 2023filed on 14 Jun 2024
- Year ended 31 Dec 2022filed on 06 Jun 2023
Bayoclin's financial analysis
- Solvency86.3%sector median: 58.2%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Bayoclin
Bayoclin's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0776.573.783
- VAT number
- BE0776573783
- Peppol
- Not found on Peppol as of 10 Nov 2026 · Check
- Legal form
- SRL
- Incorporated
- 27 Oct 2021
- Registered office
- 1402 Nivelles
- Latest accounts
- 2025 · filed on 27 Apr 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Bayoclin (SRL) has been based in Nivelles since 2021, active in: research and experimental development on biotechnology. For 2025, it reports a net profit of 181,583 € and equity of 232,832 €; its revenue is not published. Its solvency stands at 86.3%, above the median of its sector (58.2%).
Companies similar to Bayoclin
Companies in the same business, of comparable size and area, outside its group.
- NanoBiotech Research and experimental development on natural sciences and engineering Diepenbeek · balance sheet 1,834 €
- Biores Research and experimental development on natural sciences and engineering Oreye · balance sheet 271,675 €
- CH-Chog Medical Research and experimental development on natural sciences and engineering Koekelberg · balance sheet 276,747 €
- Dr. Lenaerts Patrick Research and experimental development on natural sciences and engineering Edegem · balance sheet 284,451 €
- OCTIMET Oncology Research and experimental development on natural sciences and engineering Geel · balance sheet 252,753 €
- Sustaineer Research and experimental development on natural sciences and engineering Ghent · balance sheet 299,595 €
- Hephaistos-Belgium Research and experimental development on natural sciences and engineering Liège · balance sheet 242,189 €
- PLT Analysis Research and experimental development on natural sciences and engineering Waterloo · balance sheet 305,968 €
Frequently asked questions about Bayoclin
What is the revenue of Bayoclin?
Bayoclin files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Bayoclin?
In Belgium, the VAT number is the company number prefixed with BE: BE0776573783 for Bayoclin, if the company is VAT-registered. Its company number (CBE) is 0776.573.783.
Where is the registered office of Bayoclin?
According to the CBE register, the registered office of Bayoclin is in 1402 Nivelles.
What is the equity of Bayoclin?
At the close of the 2025 financial year, the equity of Bayoclin amounts to 232,832 €, a solvency of 86.3% of total assets.
Who manages Bayoclin?
The register lists 1 active mandates at Bayoclin. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Bayoclin
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →